CA2045073A1 - Composition et traitement a base de peptides biologiquement actifs et d'antibiotiques qui inhibent l'adn-gyrase - Google Patents
Composition et traitement a base de peptides biologiquement actifs et d'antibiotiques qui inhibent l'adn-gyraseInfo
- Publication number
- CA2045073A1 CA2045073A1 CA002045073A CA2045073A CA2045073A1 CA 2045073 A1 CA2045073 A1 CA 2045073A1 CA 002045073 A CA002045073 A CA 002045073A CA 2045073 A CA2045073 A CA 2045073A CA 2045073 A1 CA2045073 A1 CA 2045073A1
- Authority
- CA
- Canada
- Prior art keywords
- peptide
- amino acid
- basic
- hydrophobic
- antibiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 159
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 27
- 229940088710 antibiotic agent Drugs 0.000 title description 5
- 108010054814 DNA Gyrase Proteins 0.000 claims abstract description 56
- 230000003115 biocidal effect Effects 0.000 claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 241000894006 Bacteria Species 0.000 claims abstract description 5
- 150000001413 amino acids Chemical class 0.000 claims description 119
- 230000002209 hydrophobic effect Effects 0.000 claims description 64
- 230000007935 neutral effect Effects 0.000 claims description 29
- 108060003100 Magainin Proteins 0.000 claims description 24
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 21
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims description 15
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 12
- 229960003405 ciprofloxacin Drugs 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000003306 quinoline derived antiinfective agent Substances 0.000 claims description 9
- 101800004819 PGLa Proteins 0.000 claims description 8
- 108050004290 Cecropin Proteins 0.000 claims description 7
- 229960000321 oxolinic acid Drugs 0.000 claims description 6
- 229960000210 nalidixic acid Drugs 0.000 claims description 5
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical group C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 101500009721 Xenopus laevis Magainin-2 Proteins 0.000 claims description 2
- MGIUUAHJVPPFEV-ABXDCCGRSA-N magainin ii Chemical group C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 MGIUUAHJVPPFEV-ABXDCCGRSA-N 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims 74
- 235000018102 proteins Nutrition 0.000 claims 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical group OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical group OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 4
- 229960004621 cinoxacin Drugs 0.000 claims 4
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical group C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 claims 4
- 235000013922 glutamic acid Nutrition 0.000 claims 4
- 239000004220 glutamic acid Substances 0.000 claims 4
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 31
- 239000002253 acid Substances 0.000 description 26
- 150000007513 acids Chemical class 0.000 description 12
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 9
- 101710176384 Peptide 1 Proteins 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 6
- 239000002674 ointment Substances 0.000 description 5
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 108010002069 Defensins Proteins 0.000 description 2
- 102000000541 Defensins Human genes 0.000 description 2
- 241000521257 Hydrops Species 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- 108010011559 alanylphenylalanine Proteins 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 description 2
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002555 ionophore Substances 0.000 description 2
- 230000000236 ionophoric effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- YCRAFFCYWOUEOF-DLOVCJGASA-N Ala-Phe-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=CC=C1 YCRAFFCYWOUEOF-DLOVCJGASA-N 0.000 description 1
- 101000600602 Aspergillus flavus (strain ATCC MYA-384 / AF70) Endopolygalacturonase A Proteins 0.000 description 1
- 101000600608 Aspergillus flavus (strain ATCC MYA-384 / AF70) Endopolygalacturonase B Proteins 0.000 description 1
- 101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 101100321992 Drosophila melanogaster ABCD gene Proteins 0.000 description 1
- 101100396994 Drosophila melanogaster Inos gene Proteins 0.000 description 1
- 101100285518 Drosophila melanogaster how gene Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101000951145 Homo sapiens Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 239000004183 Monensin A Substances 0.000 description 1
- 101100305983 Mus musculus Rom1 gene Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101800001693 R-peptide Proteins 0.000 description 1
- 101001126848 Rhizobium radiobacter Polygalacturonase Proteins 0.000 description 1
- SBMNPABNWKXNBJ-BQBZGAKWSA-N Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CO SBMNPABNWKXNBJ-BQBZGAKWSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100038014 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Human genes 0.000 description 1
- 102000018568 alpha-Defensin Human genes 0.000 description 1
- 108050007802 alpha-defensin Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940088516 cipro Drugs 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- -1 enoxac~l Chemical compound 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 108091005128 magainin I Proteins 0.000 description 1
- OFIZOVDANLLTQD-ZVNXOKPXSA-N magainin i Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)C1=CC=CC=C1 OFIZOVDANLLTQD-ZVNXOKPXSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004576 temafloxacin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54535690A | 1990-06-27 | 1990-06-27 | |
| US545,356 | 1990-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2045073A1 true CA2045073A1 (fr) | 1991-12-28 |
Family
ID=24175898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002045073A Abandoned CA2045073A1 (fr) | 1990-06-27 | 1991-06-20 | Composition et traitement a base de peptides biologiquement actifs et d'antibiotiques qui inhibent l'adn-gyrase |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0559647A1 (fr) |
| JP (1) | JPH05507718A (fr) |
| CA (1) | CA2045073A1 (fr) |
| WO (1) | WO1992000090A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654274A (en) * | 1992-06-01 | 1997-08-05 | Magainin Pharmaceuticals, Inc. | Biologically active peptides having N-terminal substitutions |
| US6348445B1 (en) | 1992-06-01 | 2002-02-19 | Magainin Pharmaceuticals, Inc. | Biologically active peptides with reduced toxicity in animals and a method for preparing same |
| US5733872A (en) * | 1993-03-12 | 1998-03-31 | Xoma Corporation | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE436645C (sv) * | 1976-04-29 | 1996-07-22 | Bonnierfoeretagen Ab | Antigeniskt aktiv polypeptid, som kan användas vid cancerdiagnosticering och vid framställning av antikroppar |
| US4659692A (en) * | 1982-11-19 | 1987-04-21 | The Regents Of The University Of California | Cationic oligopeptides having microbicidal activity |
| DE3324534A1 (de) * | 1983-07-07 | 1985-01-17 | Ciba-Geigy Ag, Basel | Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel |
| US4617149A (en) * | 1983-09-21 | 1986-10-14 | Eli Lilly And Company | Growth hormone release factor analogs |
| DE3438296A1 (de) * | 1984-04-18 | 1985-11-07 | Hoechst Ag, 6230 Frankfurt | Neue polypeptide mit blutgerinnungshemmender wirkung, verfahren zu deren herstellung bzw. gewinnung, deren verwendung und diese enthaltende mittel |
| DE3689525D1 (de) * | 1985-07-17 | 1994-02-24 | Hoechst Ag | Neue Polypeptide mit blutgerinnungshemmender Wirkung, Verfahren zu deren Herstellung bzw. Gewinnung, deren Verwendung und diese enthaltende Mittel. |
| DE3850107T2 (de) * | 1987-03-04 | 1995-02-23 | The United States Of America, Represented By The Secretary, U.S. Department Of Commerce, Springfield, Va. | Neue synthetische bioaktive verbindungen und verfahren zur herstellung bioaktiver wirkungen. |
-
1991
- 1991-06-20 JP JP91511793A patent/JPH05507718A/ja active Pending
- 1991-06-20 CA CA002045073A patent/CA2045073A1/fr not_active Abandoned
- 1991-06-20 EP EP91912701A patent/EP0559647A1/fr not_active Withdrawn
- 1991-06-20 WO PCT/US1991/004453 patent/WO1992000090A1/fr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0559647A4 (fr) | 1993-07-15 |
| WO1992000090A1 (fr) | 1992-01-09 |
| JPH05507718A (ja) | 1993-11-04 |
| EP0559647A1 (fr) | 1993-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5221664A (en) | Composition and treatment with biologically active peptides and toxic cations | |
| JPH05504566A (ja) | 生物学的活性を有するペプチドを使用した創傷処置方法 | |
| CA2086111A1 (fr) | Compositions a base de peptides bioactifs et utilisations | |
| US5208220A (en) | Composition and treatment with biologically active peptides and antibiotics which inhibit DNA gyrase | |
| US5792831A (en) | Analogues of magainin peptides containing D-amino acids | |
| US5217956A (en) | Composition and treatment with biologically active peptides and certain anions | |
| US7271239B2 (en) | D-isomers of antimicrobial peptide | |
| WO1991012015A1 (fr) | Peptides amphiphiles biologiquement actifs et procede pour inhiber la croissance de cellules cibles, de virus ou de cellules contaminees par virus | |
| CA2125494A1 (fr) | Traitement a l'aide d'une composition a base de peptides et d'agents de chelation biologiquement actifs | |
| US5654274A (en) | Biologically active peptides having N-terminal substitutions | |
| EP0590044A4 (en) | Composition and treatment with biologically active peptides having c-terminal substitutions | |
| EP0441832B1 (fr) | Composition et traitement a l'aide et peptides a activite biologique et certains anions | |
| WO2008089234A2 (fr) | Polypeptides naturels pour hygiène bucco-dentaire | |
| CA2045073A1 (fr) | Composition et traitement a base de peptides biologiquement actifs et d'antibiotiques qui inhibent l'adn-gyrase | |
| KR20180117793A (ko) | 왕귀뚜라미에서 유래한 항균 펩타이드 테레오그릴루신 2 및 그의 조성물 | |
| DE69836500T2 (de) | Antifungale und antibakterielle peptide | |
| CA2040510A1 (fr) | Composition et traitement faisant appel a des peptides biologiquement actifs et a des cations toxiques | |
| CA2180748A1 (fr) | Peptides amphiphiliques formant des canaux ioniques et presentant des modifications n-terminales | |
| EP0533795A1 (fr) | Composition et traitement utilisant des peptides biologiquement actifs contenant des resites d'aminoacides d | |
| US5254537A (en) | Composition and treatment with peptide combinations | |
| JPH04506056A (ja) | ペプチド組合せ組成物及びその用法 | |
| EP0526570A4 (en) | Composition and treatment with biologically active peptides and anti-parasitic agents or anti-fungal agents | |
| NO904846L (no) | Amfifile peptider og anvendelse derav. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |